A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Latest Information Update: 20 Jul 2023
Price :
$35 *
At a glance
- Drugs Navacaprant (Primary)
- Indications Anhedonia; Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors BlackThorn Therapeutics; Neumora Therapeutics
- 18 Jul 2023 According to Neumora Therapeutics media release, the company announced the positive End-of-Phase 2 meeting with U.S. Food and Drug Administration completed in June 2023
- 18 Jul 2023 According to Neumora Therapeutics media release, The trial originally enrolled only mild-to-moderate MDD patients in the U.S., and Neumora subsequently amended the inclusion criteria to enroll patients with moderate-to-severe MDD.
- 18 Jul 2023 Primary endpoint (Hamilton Depression Rating Scale (HAMD-17)) has not been met.